Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.73 (
urokinase-type plasminogen activator
)
10,685
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mutants of the pig kidney cell line, LLC-PK1, affected in cAMP metabolism, were examined for cAMP-dependent protein kinase (cAMP-PK) activity and for cAMP-mediated induction of
urokinase-type plasminogen activator
(
uPA
). The FIB4 and FIB6 mutant cell lines possessed about 10% parental levels of cAMP-PK activity and concomitantly reduced
uPA
production (10-20% parental) in response to calcitonin, forskolin and 8-bromo cAMP. The
FIB1
, FIB2 and FIB5 mutant cell lines had about 70% parental levels of cAMP-PK and the synthesis of
uPA
was 40-60% parental. Thus, cAMP-mediated induction of
uPA
showed a dependence on the absolute levels of cAMP-PK. However,
uPA
synthesis in response to phorbol-12-myristate-13-acetate by all of the mutants was similar to parental, which indicates that enzyme induction mediated by phorbol esters does not involve cAMP or cAMP-PK.
...
PMID:LLC-PK1 cell mutants in cAMP metabolism respond normally to phorbol esters. 301 54
